Peptide Receptor Radionuclide Therapy in a Patient with SDHB Related Grade 3 Paraganglioma (PGL) of Urinary Bladder Abstract #1833

Introduction: SDHB mutation cause aggressive metastatic PGL.36% of patients survive 5 yrs,treatment options are limited & many still being evaluated
Aim(s): 1st case of SDHB bladder PGL treated with Lu-177 DOTATATE
Materials and methods: Review presentation,biochemistry,histology,imaging,therapy effect & survival
Conference: 14th Annual ENETS conference (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Dr Rachelle Steyn
Authors: Steyn R, Prasad V
Keywords: SDHB, Bladder PGL, PRRT

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1305 PRRT for Malignant Pheochromocytomas and Paragangliomas: The Singapore General Hospital Experience
Introduction: In recent years, the use of 177Lu-DOTATATE radioisotope therapy has been expanded to patients with metastatic pheochromocytomas and paragangliomas (PCC/PGL). Although this is not the standard of care, treatment options are limited for those with MIBG negative disease. Our centre has treated over 40 patients with NETS with PRRT since 2012.
Conference: 13th Annual ENETS conference (2016)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Dr Lih Ming Loh
#1784 Peptide Receptor Radionuclide Therapy (PRRT) for Treatment of Functional and Metastatic Phaeochromocytoma (PCC) and Paraganglioma (PGL)
Introduction: Treatment options for metastatic PCC/PGL and related hypertension (HTN) are limited. Experiences in PRRT suggest favourable disease control, but lack of data on HTN response.
Conference: 14th Annual ENETS conference (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Dr Grace Kong
Keywords: PRRT
#2230 Does Somatostatin Receptor (SSR) Positive Tumor Volume Determined on Ga68 DOTANOC PET/CT in Patients with Paraganglioma (PGL)/Pheochromocytoma(PCC) Correlate with Biomarkers? An Explorative Study
Introduction: SSR PET/CT is used in workup of pts with PCC/ PGL. Correlation of tumour burden on PET & biomarkers 24 hr Urine Metanephrines (UMET), normetanephrine (UNMET), UMET:creatinine ratio (MET:Crea),UNMET:creatinine (UNMET:crea) & Chromogranin A (CGA) has not been done.
Conference: 15th Annual ENETS conference (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr Rachelle Steyn
Authors: Steyn R, Prasad V, ...
#400 Challenges in the Management of a Disseminated Malignant Abdominal Paragangliom (MPGL)
Introduction: Despite current availability of large array of Rx modalities, management of MPGLs still pose a challenge.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Mohammed Ahmed
Authors: Ahmed M, Ameen T, Bazarbashi S, ...
#246 SDHB Loss Predicts Malignancy in Pheochromocytomas/Sympathethic Paragangliomas, but Not Through Hypoxia Signalling
Introduction: To date there is no reliable histopathological marker of malignancy for pheochromocytomas/sympathetic paragangliomas (PCC/PGL). It is well-known that PCC/PGL in the hereditary context of an SDHB germline mutation very often metastasize. The immunohistochemical loss of SDHB expression was recently shown to be a surrogate marker for the presence of an SDH germline mutation in PCC/PGL. SDHB loss is supposed to be tumorigenic via activation of hypoxia signals.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dr Anja M Schmitt
Close
Notice

Dear conference participant,

Thank you for participating in the ENETS Virtual Conference 2020!

You now have the opportunity to view the webcasts, abstracts and e-posters via My ENETS. Don't miss on any of the exciting talks and take your time to view the clinical and basic science abstract sessions.

If you require a certificate of attendance, please log into My ENETS and select “Annual Conferences” from the side menu, then click on “My registrations” and select your registration for 2020. Please choose "Certificate o.A." to receive your certificate of attendance.

A note on CME accreditation:

ENETS has been liaising with UEMS regarding CME accreditation for the virtual conference. At present, we do not have a definitive answer. We will keep you updated.

 

Wishing you all the best,

The entire ENETS team